Status:
COMPLETED
Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia
Lead Sponsor:
Bayer
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
45-64 years
Phase:
PHASE2
Brief Summary
Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinar...
Eligibility Criteria
Inclusion
- Males 45 to 64 years of age
- Lower urinary tract symptoms \> 6 months
- International Prostate Symptom Score \> 12
Exclusion
- Prostate Specific Antigen \> 3 ng/ml
- Residual urine volume \> 150 m
- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
- Nitrate use
- Other exclusion criteria apply acc. to Summary of Product Characteristics
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT00657839
Start Date
October 1 2005
End Date
June 1 2006
Last Update
October 28 2014
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Biberach, Baden-Württemberg / 277, Germany, 88400
2
München, Bayern / 280, Germany, 81925
3
Rosenheim, Bayern / 280, Germany, 83022
4
Starnberg, Bayern / 280, Germany, 82319